Jacobs Levy Equity Management, Inc Mersana Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 993,046 shares of MRSN stock, worth $2.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
993,046
Previous 485,593
104.5%
Holding current value
$2.5 Million
Previous $976,000
92.21%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding MRSN
# of Institutions
121Shares Held
116MCall Options Held
233KPut Options Held
74K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$48.8 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$30.4 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$28.5 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$21.8 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$21.1 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $245M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...